146 related articles for article (PubMed ID: 24513870)
1. The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist.
Tannheimer SL; Sorensen EA; Cui ZH; Kim M; Patel L; Baker WR; Phillips GB; Wright CD; Salmon M
J Pharmacol Exp Ther; 2014 Apr; 349(1):85-93. PubMed ID: 24513870
[TBL] [Abstract][Full Text] [Related]
2. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells.
Joshi T; Yan D; Hamed O; Tannheimer SL; Phillips GB; Wright CD; Kim M; Salmon M; Newton R; Giembycz MA
J Pharmacol Exp Ther; 2017 Feb; 360(2):324-340. PubMed ID: 27927912
[TBL] [Abstract][Full Text] [Related]
3. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
[TBL] [Abstract][Full Text] [Related]
4. The in vivo efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting β 2-adrenoceptor agonist in preclinical animal species.
Salmon M; Tannheimer SL; Gentzler TT; Cui ZH; Sorensen EA; Hartsough KC; Kim M; Purvis LJ; Barrett EG; McDonald JD; Rudolph K; Doyle-Eisele M; Kuehl PJ; Royer CM; Baker WR; Phillips GB; Wright CD
Pharmacol Res Perspect; 2014 Aug; 2(4):e00046. PubMed ID: 25505595
[TBL] [Abstract][Full Text] [Related]
5. Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
Shan WJ; Huang L; Zhou Q; Jiang HL; Luo ZH; Lai KF; Li XS
Bioorg Med Chem Lett; 2012 Feb; 22(4):1523-6. PubMed ID: 22297114
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.
Huang L; Shan W; Zhou Q; Xie J; Lai K; Li X
Bioorg Med Chem Lett; 2014 Jan; 24(1):249-53. PubMed ID: 24300734
[TBL] [Abstract][Full Text] [Related]
7. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.
BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R
Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049
[TBL] [Abstract][Full Text] [Related]
8. Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.
Liu A; Huang L; Wang Z; Luo Z; Mao F; Shan W; Xie J; Lai K; Li X
Bioorg Med Chem Lett; 2013 Mar; 23(5):1548-52. PubMed ID: 23375225
[TBL] [Abstract][Full Text] [Related]
9. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Tannheimer SL; Wright CD; Salmon M
Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
[TBL] [Abstract][Full Text] [Related]
10. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
[TBL] [Abstract][Full Text] [Related]
11. Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.
McKinnell RM; Klein U; Linsell MS; Moran EJ; Nodwell MB; Pfeiffer JW; Thomas GR; Yu C; Jacobsen JR
Bioorg Med Chem Lett; 2014 Jul; 24(13):2871-6. PubMed ID: 24835980
[TBL] [Abstract][Full Text] [Related]
12. Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.
Joshi R; Yan D; Hamed O; Mostafa MM; Joshi T; Newton R; Giembycz MA
Mol Pharmacol; 2019 Jul; 96(1):56-72. PubMed ID: 31036559
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.
Hegde SS; Hughes AD; Chen Y; Steinfeld T; Jasper JR; Lee TW; McNamara A; Martin WJ; Pulido-Rios MT; Mammen M
J Pharmacol Exp Ther; 2014 Oct; 351(1):190-9. PubMed ID: 25100753
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells.
Patel BS; Prabhala P; Oliver BG; Ammit AJ
Am J Respir Cell Mol Biol; 2015 May; 52(5):634-40. PubMed ID: 25296132
[TBL] [Abstract][Full Text] [Related]
16. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
Asaka N; Kakuo H; Ohmori K; Sasaki E; Togawa M; Yamada S; Oka T; Kiniwa M
Arzneimittelforschung; 2010; 60(9):564-70. PubMed ID: 21117500
[TBL] [Abstract][Full Text] [Related]
17. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
Moretto N; Caruso P; Bosco R; Marchini G; Pastore F; Armani E; Amari G; Rizzi A; Ghidini E; De Fanti R; Capaldi C; Carzaniga L; Hirsch E; Buccellati C; Sala A; Carnini C; Patacchini R; Delcanale M; Civelli M; Villetti G; Facchinetti F
J Pharmacol Exp Ther; 2015 Mar; 352(3):559-67. PubMed ID: 25576075
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
19. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
